Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).


Options:
A: Postmenopausal women ages 50 to 79.
B: Inclusion Criteria

* Absence of menstrual period for 12 months but not more than 5 years, or absence of menstrual period for 6 to 12 months and follicle stimulating factor (FSH) greater than 40 IU/L

Exclusion Criteria

* Treatment with estrogens, progesterone, raloxifene, or tamoxifen
* Treatment with bisphosphonates, calcitonin, fluoride, or systemic corticosteroids
* Use of soy/herbal supplements, including DHEA, within 3 months prior to study entry
* Use of antibiotics in the month prior to study entry
* Use of prescription medication to treat hot flashes
* Chemical menopause, including post-chemotherapy
* Hyperthyroidism
* Hypothyroidism
* Uncontrolled diabetes
* Malabsorption syndromes or other chronic diseases
* Body mass index (BMI) less than 20 or greater than 32
* Bone mineral density (BMD) T-score below -2.0 in lumbar spine or femoral neck
C: Inclusion Criteria:

* Postmenopausal, defined as no vaginal bleeding for at least 1 year and serum estradiol level lower than 20 pg/ml

Exclusion Criteria:

* Signs, symptoms or personal history of cardiovascular disease
* Diabetes mellitus or fasting serum glucose of 126 mg/dL or greater
* Fasting plasma triglyceride of 500 mg/dL or greater
* Serum creatinine greater than 2.0 mg/dL
* Uncontrolled hypertension
* Untreated thyroid disease
* Life expectancy less than 5 years
* Current use of hormone replacement therapy (HRT)
* Soy, nut, or related food allergies
* More than 5 alcohol drinks per day or substance abuse
D: Inclusion Criteria:

* female
* age 45 - 55
* peri- or post-menopausal
* moderate to severe vasomotor symptoms
* normal thyroid stimulating hormone
* proof of normal mammogram within past 2 years

Exclusion Criteria:

* use of HT or oral contraceptives within past 3 months
* use of herbs or alternative or complementary medicines for vasomotor symptoms within past 1 month
* medical history of contraindications to HT
* bone mineral density greater than 2 standard deviations below age specific mean
* bilateral oophorectomy
* current use of tamoxifen, raloxifene, bisphosphonates, cholesterol-lowering medications, prescription blood-thinners, or oral steroids
* pregnant or planning to become pregnant
* allergy to soybeans or soy protein
* unable to swallow pills
* current participation in another investigational drug trial
* intention to move out of area in the next 12 months
* non-compliance with procedures involved in screening and run-in trial

Answer: A